Bionomics to re-domicile from Australia to US via scheme of arrangement with Neuphoria

Neuphoria Therapeutics Inc.

Holders receive 1 Neuphoria share per 1,440 ordinary shares or per 8 ADSs; estimated post-domicile Nasdaq price ~$3.50.
Board unanimously recommends approval; shareholder vote expected late Nov 2024, implementation early Dec 2024.
Re-domicile driven by loss of foreign private issuer status, reduced compliance costs, and greater US investor access.
No material change to assets, management, operations, or strategy expected; structure designed to be tax-neutral.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.